Given this, they extended their study to CD34+ CML cells and concluded that pioglitazone may have the ability to eradicate the population of leukemic stem cells (LSCs)—a group of neoplastic cells which widely participate in induction of chemo‐resistance (Prost et al., 2015). The gene discussed is CD34; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.